dc.date.accessioned | 2022-10-29T15:08:03Z | |
dc.date.available | 2022-10-29T15:08:03Z | |
dc.date.created | 2022-10-10T09:54:56Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Søraas, Arne Vasli Grødeland, Gunnveig Granerud, Beathe Kiland Ueland, Thor Lind, Andreas Fevang, Børre Murphy, Sarah Louise Mikalsen Huse, Camilla Nygaard, Anders Benteson Steffensen, Anne Katrine Al-Baldawi, Huda Holberg-Petersen, Mona Andresen, Lise Lima Ågnes, Camilla Ranheim, Trine Schanke, Ylva Istre, Mette Stausland Dahl, John Arne Chopra, Adity Dudman, Susanne Kaarbø, Mari Andersen, Jan Terje Vaage, Eline Benno Tran, Trung The Vaage, John Torgils Michelsen, Annika Elisabet Müller, Fredrik Aukrust, Pål Halvorsen, Bente Evy Dahl, Tuva Børresdatter Holter, Jan Cato Lund-Johansen, Fridtjof . Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity. Frontiers in Immunology. 2022, 13, 1-12 | |
dc.identifier.uri | http://hdl.handle.net/10852/97411 | |
dc.description.abstract | Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant. | |
dc.description.abstract | Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity | |
dc.title.alternative | ENEngelskEnglishBreakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity | |
dc.type | Journal article | |
dc.creator.author | Søraas, Arne Vasli | |
dc.creator.author | Grødeland, Gunnveig | |
dc.creator.author | Granerud, Beathe Kiland | |
dc.creator.author | Ueland, Thor | |
dc.creator.author | Lind, Andreas | |
dc.creator.author | Fevang, Børre | |
dc.creator.author | Murphy, Sarah Louise Mikalsen | |
dc.creator.author | Huse, Camilla | |
dc.creator.author | Nygaard, Anders Benteson | |
dc.creator.author | Steffensen, Anne Katrine | |
dc.creator.author | Al-Baldawi, Huda | |
dc.creator.author | Holberg-Petersen, Mona | |
dc.creator.author | Andresen, Lise Lima | |
dc.creator.author | Ågnes, Camilla | |
dc.creator.author | Ranheim, Trine | |
dc.creator.author | Schanke, Ylva | |
dc.creator.author | Istre, Mette Stausland | |
dc.creator.author | Dahl, John Arne | |
dc.creator.author | Chopra, Adity | |
dc.creator.author | Dudman, Susanne | |
dc.creator.author | Kaarbø, Mari | |
dc.creator.author | Andersen, Jan Terje | |
dc.creator.author | Vaage, Eline Benno | |
dc.creator.author | Tran, Trung The | |
dc.creator.author | Vaage, John Torgils | |
dc.creator.author | Michelsen, Annika Elisabet | |
dc.creator.author | Müller, Fredrik | |
dc.creator.author | Aukrust, Pål | |
dc.creator.author | Halvorsen, Bente Evy | |
dc.creator.author | Dahl, Tuva Børresdatter | |
dc.creator.author | Holter, Jan Cato | |
dc.creator.author | Lund-Johansen, Fridtjof | |
cristin.unitcode | 185,53,18,12 | |
cristin.unitname | Immunologi og transfusjonsmedisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2059925 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Immunology&rft.volume=13&rft.spage=1&rft.date=2022 | |
dc.identifier.jtitle | Frontiers in Immunology | |
dc.identifier.volume | 13 | |
dc.identifier.doi | https://doi.org/10.3389/fimmu.2022.964525 | |
dc.subject.nvi | VDP::Medisinsk mikrobiologi: 715VDP::Medisinsk immunologi: 716 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1664-3224 | |
dc.type.version | PublishedVersion | |
cristin.articleid | 964525 | |
dc.relation.project | NFR/312780 | |
dc.relation.project | NFR/324274 | |
dc.relation.project | HSØ/2019067, 2021071, 2021047, 33612, 2021087, 10357, 2017092 | |
dc.relation.project | EC/HEU/848099 | |
dc.relation.project | EC/HEU/71029 | |
dc.relation.project | OUS/Fredrik Müller | |